TG Therapeutics Stock Forecast for 2023 - 2025 - 2030

Updated on 02/04/2023

Stock Rating
9
Price Target
$19.00
Consensus
Outperform
Upside
9.45%
Analysts
1
Stock Rating
9
Upside
9.45%
Analysts
1
Price Target
$19.00

TG Therapeutics Stock Forecast and Price Target

The average price target for TG Therapeutics's stock set by recognized analysts recently is $19.00, which would result in a potential upside of approximately 9.45% if it reached this mark. The estimation is based on a high estimate of $40.00 and a low estimate of $4.00.

$19.00

9.45% Upside

Outperform
Outperform

TG Therapeutics Fair Value Forecast for 2023 - 2025 - 2030

TG Therapeutics's Price has grown In the last two years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $17.16 – an increase of 100.00%. For the next nine years, experts predict that TG Therapeutics's Fair Value will grow at a rate of 100.00%.

2022 Fair Value Forecast
$17.16
2023 Fair Value Forecast
$19.11
2024 Fair Value Forecast
$21.24
2025 Fair Value Forecast
$23.62
2026 Fair Value Forecast
$26.26
2027 Fair Value Forecast
$29.20
2028 Fair Value Forecast
$32.47
2029 Fair Value Forecast
$36.11
2030 Fair Value Forecast
$40.15

TG Therapeutics Revenue Forecast for 2023 - 2025 - 2030

TG Therapeutics's Revenue has grown In the last two years, rising from $150.00k to $6.69M – a growth of 4360.00%. In the next year, 0 analysts estimate that TG Therapeutics's Revenue will decrease by 65.17%, reaching $2.33M. According to professional forecasts, in 2030, TG Therapeutics's Revenue will decrease by 34.77%, reaching $4.36M.

2022 Rev Forecast
$0.00B
2023 Rev Forecast
$0.00B
2024 Rev Forecast
$0.00B
2025 Rev Forecast
$0.01B
2026 Rev Forecast
$0.00B
2027 Rev Forecast
$0.00B
2028 Rev Forecast
$0.00B
2029 Rev Forecast
$0.00B
2030 Rev Forecast
$0.00B

TG Therapeutics Dividend per Share Forecast for 2023 - 2025 - 2030

TG Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, TG Therapeutics's Free Cash Flow has grown, moving from $-132.94M to $-296.03M – an increase of 122.68%. 0 analysts predict TG Therapeutics's Free Cash Flow will decrease by 30.99% in the next year, reaching $-204.29M. By 2030, professionals predict that TG Therapeutics's Free Cash Flow will decrease by 24.91%, to $-222.30M.

2022 FCF Forecast
$-204290303.00
2023 FCF Forecast
$-190235130.15
2024 FCF Forecast
$-206011963.61
2025 FCF Forecast
$-236666543.80
2026 FCF Forecast
$-226237438.10
2027 FCF Forecast
$-214171441.40
2028 FCF Forecast
$-212236759.38
2029 FCF Forecast
$-220124892.27
2030 FCF Forecast
$-222296791.21

TG Therapeutics Net Income Forecast for 2023 - 2025 - 2030

In the last two years, TG Therapeutics's Net Income has grown by 101.37%, rising from $-172.87M to $-348.10M. In the following year, 0 experts forecast that TG Therapeutics's Net Income will decrease by 25.87%, to $-258.06M. In 2030, professionals predict that TG Therapeutics's Net Income will decrease by 21.41%, to $-273.56M.

2022 NI Forecast
$-258058133.33
2023 NI Forecast
$-238299482.26
2024 NI Forecast
$-256918615.14
2025 NI Forecast
$-287688901.28
2026 NI Forecast
$-278425318.66
2027 NI Forecast
$-264856724.79
2028 NI Forecast
$-262870299.36
2029 NI Forecast
$-270940417.55
2030 NI Forecast
$-273559508.25

TG Therapeutics EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, TG Therapeutics's EBITDA has seen an increase, rising from $-168.96M to $-344.49M. This represents a growth of 103.89%. For the following year, the 0 analysts predict that TG Therapeutics's EBITDA will drop by 26.48%, reaching $-253.26M. In 2030, the professionals' prediction is that TGTX's EBITDA will decrease by 21.85%, reaching $-269.21M.

2022 EBITDA Forecast
$-253257565.00
2023 EBITDA Forecast
$-234001548.14
2024 EBITDA Forecast
$-252433070.08
2025 EBITDA Forecast
$-283524409.88
2026 EBITDA Forecast
$-274035792.96
2027 EBITDA Forecast
$-260507559.32
2028 EBITDA Forecast
$-258492967.53
2029 EBITDA Forecast
$-266618263.14
2030 EBITDA Forecast
$-269213347.57

TG Therapeutics EBIT Forecast for 2023 - 2025 - 2030

TG Therapeutics's EBIT has seen growth In the last two years, going from $-169.06M to $-344.77M – a gain of 103.93% In the following year, the 0 analysts surveyed believe that TG Therapeutics's EBIT will decrease by 26.50%, reaching $-253.39M. According to professionals, by 2030, TG Therapeutics's EBIT will have decreased by 21.86%, falling down to $-269.41M.

2022 EBIT Forecast
$-253394457.67
2023 EBIT Forecast
$-234136478.88
2024 EBIT Forecast
$-252586433.42
2025 EBIT Forecast
$-283730340.66
2026 EBIT Forecast
$-274225374.25
2027 EBIT Forecast
$-260687781.61
2028 EBIT Forecast
$-258671796.10
2029 EBIT Forecast
$-266811335.28
2030 EBIT Forecast
$-269408298.94

TG Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030

TG Therapeutics's EPS has grown In the last two years, rising from $-1.96 to $-2.63 – a growth of 34.18%. In the next year, 0 analysts estimate that TG Therapeutics's EPS will decrease by 11.66%, reaching $-2.32. According to professional forecasts, in 2030, TG Therapeutics's EPS will decrease by 10.44%, reaching $-2.36.

2022 EPS Forecast
$-2.32
2023 EPS Forecast
$-2.22
2024 EPS Forecast
$-2.29
2025 EPS Forecast
$-2.40
2026 EPS Forecast
$-2.38
2027 EPS Forecast
$-2.32
2028 EPS Forecast
$-2.31
2029 EPS Forecast
$-2.34
2030 EPS Forecast
$-2.36